Influenza vaccinations - Who needs them and when?

被引:14
作者
Hak, E [1 ]
Hoes, AW [1 ]
Verheij, TJM [1 ]
机构
[1] UMC Utrecht, Julius Ctr Hlth Sci & Primary Care, NL-3508 AB Utrecht, Netherlands
关键词
D O I
10.2165/00003495-200262170-00001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Influenza vaccination programmes should aim at reducing the burden from influenza among those who need it most. The primary aim of this literature review is to identify who should receive priority in influenza vaccination programmes. Risk factors for severe post-influenza complications include immune-related factors, such as ageing or the presence of immune-suppression, respiratory tract disease, proneness to exacerbation of concomitant high-risk disease, potential adverse effects associated with long-term drug use or residence in closed communities with high transmission rate. When given annually in autumn, inactivated trivalent influenza vaccines can reduce severe complications from influenza among persons aged 65 years or older by 30-60%. Among children aged less than 7 years, notably those with asthma, the occurrence of otitis media or acute respiratory disease is reduced by 20-75% with vaccination. In addition, vaccination of residents of long-term care facilities and their personnel leads to a 42% reduction in mortality among patients. However, uncertainty remains about whether influenza vaccination can reduce complications from influenza among the large group of older children and persons of working-age with high-risk disease. To further increase the impact of prevention strategies, the development and application of clinical prediction rules to estimate absolute risks of post-influenza complications should be studied in relation to optimal vaccine delivery strategies. Furthermore, adequately powered studies should be conducted to demonstrate possible effectiveness of vaccination in reducing post-influenza complications among older children and working-age adults.
引用
收藏
页码:2413 / 2420
页数:8
相关论文
共 67 条
  • [1] REDUCTION IN MORTALITY ASSOCIATED WITH INFLUENZA VACCINE DURING 1989-90 EPIDEMIC
    AHMED, AEH
    NICHOLSON, KG
    NGUYENVANTAM, JS
    [J]. LANCET, 1995, 346 (8975): : 591 - 595
  • [2] Influenza vaccination for healthy young adults
    Ahmed, F
    Singleton, JA
    Franks, AL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (21) : 1543 - 1547
  • [3] Influenza vaccination in 29 countries - An update to 1997
    Ambrosch, F
    Fedson, DS
    [J]. PHARMACOECONOMICS, 1999, 16 (Suppl 1) : 47 - 54
  • [4] [Anonymous], 1998, MMWR Recomm Rep, V47, P1
  • [5] PNEUMONIA AND INFLUENZA DEATHS DURING EPIDEMICS - IMPLICATIONS FOR PREVENTION
    BARKER, WH
    MULLOOLY, JP
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1982, 142 (01) : 85 - 89
  • [6] IMMUNIZATION WITH KILLED INFLUENZA-VIRUS IN CHILDREN WITH CHRONIC ASTHMA
    BELL, TD
    CHAI, H
    BERLOW, B
    DANIELS, G
    [J]. CHEST, 1978, 73 (02) : 140 - 145
  • [7] The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children
    Belshe, RB
    Mendelman, PM
    Treanor, J
    King, J
    Gruber, WC
    Piedra, P
    Bernstein, DI
    Hayden, FG
    Kotloff, K
    Zangwill, K
    Iacuzio, D
    Wolff, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (20) : 1405 - 1412
  • [8] Protection against influenza after annually repeated vaccination -: A meta-analysis of serologic and field studies
    Beyer, WEP
    de Bruijn, IA
    Palache, AM
    Westendorp, RGJ
    Osterhaus, ADME
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (02) : 182 - 188
  • [9] Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy A meta-analysis
    Beyer, WEP
    Palache, AM
    de Jong, JC
    Osterhaus, ADME
    [J]. VACCINE, 2002, 20 (9-10) : 1340 - 1353
  • [10] The immunogenicity of influenza virus vaccine in solid organ transplant recipients
    Blumberg, EA
    Albano, C
    Pruett, T
    Isaacs, R
    Fitzpatrick, J
    Bergin, J
    Crump, C
    Hayden, FG
    [J]. CLINICAL INFECTIOUS DISEASES, 1996, 22 (02) : 295 - 302